Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). If […]
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Zymeworks Announces Additional Leadership Appointments
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
Zymeworks Added to Nasdaq Biotechnology Index
Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral […]
Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results
Zymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference
We are pleased to present preclinical data associated with our Trispecific T Cell Engager (TriTCE) therapeutic programs in two poster presentations at the annual SITC Conference, taking place November 1-4 in San Diego, CA. The poster presentation titled “TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the […]
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the European Society of Medical Oncology (ESMO) Annual Congress taking place October 20-24 in Madrid, Spain. Poster Presentation Information: Title: Zanidatamab (zani) […]
Zymeworks To Host Third Quarter 2023 Results Conference Call
